Merck won U.S. FDA approval for Idvynso, a two-drug oral HIV regimen, ahead of its PDUFA window. The decision covers adults with HIV-1 who are already virologically suppressed and have no history of virologic treatment failure, with the added constraint of no known resistance substitutions to doravirine.